Starlight Cardiovascular
CEO: Beverly Tang
Starlight Cardiovascular is developing much needed tools and devices to treat pediatric congenital heart defects (CHDs). Approximately 1.3 million babies are born each year with a CHD. Most of the tools used to treat these children were designed for adult conditions and anatomy, limiting their utility for pediatric patients. Starlight Cardiovascular is developing a portfolio of devices designed and tested specifically for pediatric CHD with the goals of improving morbidity, mortality, and access to care.